- Study at Deakin
- Life at Deakin
- Industry and community
- About Deakin
Note: The 2012, 2013, 2014 publications have not been audited.
Thomas J. Kaley may be from another institution or only recently joined Deakin University.
Omuro, Antonio*, Chan, Timothy A.*, Abrey, Lauren E.*, Khasraw, Mustafa*, Reiner, Anne S.*, Kaley, Thomas J.*, DeAngelis, Lisa M.*, Lassman, Andrew B.*, Nolan, Craig P.*, Gavrilovic, Igor T.*, Hormigo, Adilia*, Salvant, Cynthia*, Heguy, Adriana*, Kaufman, Andrew*, Huse, Jason T.*, Panageas, Katherine S.*, Hottinger, Andreas F.* and Mellinghoff, Ingo* (2013) Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma, Neuro-Oncology, vol. 15, no. 2, pp. 242-250, Oxford University Press, Cary, N. C. [C1.1]
ERA journal ID: 16656 – Scopus EID: 2-s2.0-84875709160
Citation counts: Scopus - 10, Thomson - 7
DRO entry for this publication
No grants and/or consultancies found or audited – the 2014 HERDC financial return has not been completed or loaded as yet.
No completions found or audited.
DRO to publications collection last synchronised: Thursday 30th October 2014 10:04pm